FindTrial
Sign In

Value of procalcitonin combined with serum amyloid A in predicting early infection and prognosis in severe patients

Value of procalcitonin combined with serum amyloid A in predicting early infection and prognosis in severe patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200056276
Enrollment
Unknown
Registered
2022-02-03
Start date
2022-02-21
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical illness

Interventions

Case series:None

Sponsors

Huizhou Municipal Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Patients who stayed at ICU for more than 24 hours; 2. Aged more than 15 years old; 3. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with thyroid diseases such as thyroid tumors; 2. Repeat inpatient; 3. Infection was confirmed when entering ICU.

Design outcomes

Primary

MeasureTime frame
serum amyloid A;procalcitonin;—

Countries

China

Contacts

Public ContactRong QU

Huizhou Municipal Central Hospital

hzqurong@126.com+86 138 2991 2988

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026